Form D · Biotechnology
TripleBar Bio, Inc.
Emeryville, CA · CIK 0001998555
Offering snapshot reported Oct 25, 2023 · SEC filing
- Reported sold
- $19.8M Offering amount: $20.5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 16, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 25, 2023 | Initial | $19,763,632 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-495601
The total amount sold including conversion of convertible notes and Series A preferred stock for a total of $5,524,996.31.
Source: Form D, filed Oct 25, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Maria Cho | Director, Executive |
| David Friedberg | Director |
| Howard Levin | Director |
| Rose Wardle | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1250 45 Th St Ste 315
Emeryville, CA, 94608
Emeryville, CA, 94608